Clinical Trial Update: Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the combination of venetoclax with high-dose ibrutinib in chronic lymphocytic leukemia and small lymphocytic lymphoma that p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)
• Venetoclax (venetoclax)

Snippet

Sponsor: Michael Choi | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING